Dong Dong, Jia Li, Zhou Yunli, Ren Li, Li Juan, Zhang Jun
Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin׳s Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, PR China.
Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry, Tianjin Medical University, Tianjin, PR China.
Urol Oncol. 2017 May;35(5):279-285. doi: 10.1016/j.urolonc.2016.12.017. Epub 2017 Jan 19.
This study aimed to determine the serum levels of angiopoietin-like 4 (ANGPTL4) in patients with renal cell carcinoma (RCC) and explore its potential as a biomarker.
Blood samples were taken from 110 patients with RCC, 66 healthy controls, and patients with other solid tumors. Serum ANGPTL4 levels were measured using the enzyme-linked immunosorbent assay, and their correlation with clinical characteristics was further analyzed. Received operating characteristic (ROC) curves, Kaplan-Meier curves, and log-rank analyses were used to evaluate diagnostic and prognostic significance.
Serum ANGPTL4 levels were significantly higher in patients with RCC compared with healthy controls and patients with other types of cancers (P<0.0001) and associated with sex, Fuhrman grades, metastasis states, and tumor node metastasis stages (P<0.05), but not with age, tumor size, and histological types (P>0.05). The ROCs/area under the ROC curve analysis indicated an area under the ROC curve of 0.844 (sensitivity = 0.691; specificity = 0.939) and 0.725 (sensitivity = 0.909; specificity = 0.568), respectively, to distinguish patients with RCC from healthy controls and those with metastasis from those without metastasis. The survival analysis revealed that patients with low serum ANGPTL4 had longer progression-free survival compared with those with high serum ANGPTL4 (P = 0.033).
The present study suggested that the elevated serum ANGPTL4 level might be a novel diagnostic and prognostic biomarker for patients with RCC.
本研究旨在测定肾细胞癌（RCC）患者血清血管生成素样4（ANGPTL4）水平，并探讨其作为生物标志物的潜力。
采集110例RCC患者、66例健康对照者及其他实体瘤患者的血样。采用酶联免疫吸附测定法检测血清ANGPTL4水平，并进一步分析其与临床特征的相关性。采用受试者工作特征（ROC）曲线、Kaplan-Meier曲线和对数秩分析来评估诊断和预后意义。
与健康对照者和其他类型癌症患者相比，RCC患者血清ANGPTL4水平显著升高（P<0.0001），且与性别、Fuhrman分级、转移状态和肿瘤淋巴结转移分期相关（P<0.05），但与年龄、肿瘤大小和组织学类型无关（P>0.05）。ROC曲线下面积分析显示，区分RCC患者与健康对照者以及有转移与无转移患者的ROC曲线下面积分别为0.844（敏感性=0.691；特异性=0.939）和0.725（敏感性=0.909；特异性=0.568）。生存分析显示，血清ANGPTL4水平低的患者无进展生存期长于血清ANGPTL4水平高的患者（P = 0.033）。
本研究表明，血清ANGPTL4水平升高可能是RCC患者一种新的诊断和预后生物标志物。
